SERUM INTERLEUKIN-34 LEVEL AT PATIENTS WITH CHRONIC HEPATITIS B''


Creative Commons License

Çakal B.

X. INTERNATIONAL ISTANBUL SCIENTIFIC RESEARCH CONGRESS, İstanbul, Türkiye, 23 - 25 Temmuz 2022, ss.135-138

  • Yayın Türü: Bildiri / Tam Metin Bildiri
  • Basıldığı Şehir: İstanbul
  • Basıldığı Ülke: Türkiye
  • Sayfa Sayıları: ss.135-138
  • İstanbul Üniversitesi Adresli: Evet

Özet

ABSTRACT

Background and Aim: Genetic and immunological factors of the infected individual are important on the formation and prognosis of liver diseases associated with the natural course of chronic hepatitis B virus (HBV) infection. In this study, it was aimed to evaluate the relationship between clinical laboratory, virological and histological results and serum interleukin (IL)-34 levels of patients with chronic hepatitis B (CHB)

Material and Method: This study included 50 chronic hepatitis B patients who were underwent liver parenchymal biopsy. A commercial kit working with the ELISA principle was used to determine the serum IL-34 levels of the patients. Histological evaluation of liver tissue samples of the patients was performed using the Ishak modified histological activity index system. There was no statistically significant correlation between serum IL-34 levels and patients’ clinical laboratory, viral loads and histopathological data including AST and ALT (p>0.05).

Results: The mean aspartate aminotrasferase (AST), alanine aminotrasferase (ALT), HBV DNA inflammation (grade) and fibrosis (stage) levels of the patients were 60.24±65.87, 78.82±114.30, 6.95±7.46 log IU/ml, 6.44±3.32 and 2.7±1.16, respectively. Conclusion: Serum IL-34 levels are not associated with clinical and histological outcomes in patients with CHB.

Keywords: Interleukin 34, Hepatitis B virüs, clinic laboratory, viral load, liver fibrosis